Follow
Brendan T. Griffin
Brendan T. Griffin
School of Pharmacy, University College Cork, Ireland
Verified email at ucc.ie - Homepage
Title
Cited by
Cited by
Year
Biopharmaceutical challenges associated with drugs with low aqueous solubility—the potential impact of lipid-based formulations
CM O'driscoll, BT Griffin
Advanced drug delivery reviews 60 (6), 617-624, 2008
3592008
Gut reactions: breaking down xenobiotic–microbiome interactions
G Clarke, KV Sandhu, BT Griffin, TG Dinan, JF Cryan, NP Hyland
Pharmacological reviews 71 (2), 198-224, 2019
2752019
Lipid-based nanocarriers for oral peptide delivery
Z Niu, I Conejos-Sánchez, BT Griffin, CM O’Driscoll, MJ Alonso
Advanced drug delivery reviews 106, 337-354, 2016
2442016
Interactions between antidepressants and P‐glycoprotein at the blood–brain barrier: clinical significance of in vitro and in vivo findings
FE O'Brien, TG Dinan, BT Griffin, JF Cryan
British journal of pharmacology 165 (2), 289-312, 2012
2272012
Impact of gastrointestinal tract variability on oral drug absorption and pharmacokinetics: An UNGAP review
Z Vinarov, M Abdallah, JAG Agundez, K Allegaert, AW Basit, ...
European Journal of Pharmaceutical Sciences 162, 105812, 2021
1772021
From belly to brain: targeting the ghrelin receptor in appetite and food intake regulation
K Howick, BT Griffin, JF Cryan, H Schellekens
International journal of molecular sciences 18 (2), 273, 2017
1642017
Focus: microbiome: the impact of the gut microbiota on drug metabolism and clinical outcome
EF Enright, CGM Gahan, SA Joyce, BT Griffin
The Yale journal of biology and medicine 89 (3), 375, 2016
1512016
Comparison of in vitro tests at various levels of complexity for the prediction of in vivo performance of lipid-based formulations: case studies with fenofibrate
BT Griffin, M Kuentz, M Vertzoni, ES Kostewicz, Y Fei, W Faisal, C Stillhart, ...
European Journal of Pharmaceutics and Biopharmaceutics 86 (3), 427-437, 2014
1362014
Drug–gut microbiota interactions: implications for neuropharmacology
J Walsh, BT Griffin, G Clarke, NP Hyland
British journal of pharmacology 175 (24), 4415-4429, 2018
1102018
Lipophilicity and hydrophobicity considerations in bio-enabling oral formulations approaches–a PEARRL review
F Ditzinger, DJ Price, AR Ilie, NJ Köhl, S Jankovic, G Tsakiridou, ...
Journal of Pharmacy and Pharmacology 71 (4), 464-482, 2019
1022019
Impact of body composition parameters on clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with docetaxel
SJ Cushen, DG Power, KP Murphy, R McDermott, BT Griffin, M Lim, ...
Clinical nutrition ESPEN 13, e39-e45, 2016
1012016
Pharmacotherapy for neonatal seizures: current knowledge and future perspectives
MD Donovan, BT Griffin, L Kharoshankaya, JF Cryan, GB Boylan
Drugs 76 (6), 647-661, 2016
1012016
Food for thought: formulating away the food effect–a PEARRL review
JP O'Shea, R Holm, CM O'Driscoll, BT Griffin
Journal of Pharmacy and Pharmacology 71 (4), 510-535, 2019
992019
Current challenges and future perspectives in oral absorption research: An opinion of the UNGAP network
Z Vinarov, B Abrahamsson, P Artursson, H Batchelor, P Berben, ...
Advanced Drug Delivery Reviews 171, 289-331, 2021
972021
Lactococcus lactis as a cell factory for delivery of therapeutic proteins
M Bahey-El-Din, CGM Gahan, BT Griffin
Current gene therapy 10 (1), 34-45, 2010
972010
Regulation of biosimilar medicines and current perspectives on interchangeability and policy
J O’Callaghan, SP Barry, M Bermingham, JM Morris, BT Griffin
European journal of clinical pharmacology 75, 1-11, 2019
952019
A comparison of intestinal lymphatic transport and systemic bioavailability of saquinavir from three lipid‐based formulations in the anaesthetised rat model
BT Griffin, CM O'driscoll
Journal of pharmacy and pharmacology 58 (7), 917-925, 2006
952006
Pharmacokinetic, pharmacodynamic and biodistribution following oral administration of nanocarriers containing peptide and protein drugs
BT Griffin, J Guo, E Presas, MD Donovan, MJ Alonso, CM O'Driscoll
Advanced Drug Delivery Reviews 106, 367-380, 2016
932016
Microbiome-mediated bile acid modification: role in intestinal drug absorption and metabolism
EF Enright, BT Griffin, CGM Gahan, SA Joyce
Pharmacological Research 133, 170-186, 2018
822018
Lactococcus lactis-expressing listeriolysin O (LLO) provides protection and specific CD8+ T cells against Listeria monocytogenes in the murine infection model
M Bahey-El-Din, PG Casey, BT Griffin, CGM Gahan
Vaccine 26 (41), 5304-5314, 2008
712008
The system can't perform the operation now. Try again later.
Articles 1–20